-+ 0.00%
-+ 0.00%
-+ 0.00%

CareDx publishes 2025 annual report

PUBT·04/30/2026 22:28:26
Listen to the news
CareDx publishes 2025 annual report
  • CareDx filed its annual report for fiscal year ended Dec. 31, 2025, outlining a strategy built around profitable growth, operational efficiency, and expansion into adjacent transplant-related markets under TRANSPLANT+.
  • Business remained centered on transplant surveillance testing, supported by lab products, digital workflow tools, and pharmacy services aimed at increasing transplant-center adoption and patient adherence.
  • CareDx performed about 200,000 commercial tests during 2025 from its Brisbane, California laboratory.
  • HeartCare expanded its indication in 2025 to include pediatric patients from birth, extending use of combined gene-expression and dd-cfDNA surveillance in heart transplant care.
  • Medicare reimbursement risk stayed in focus as draft coverage proposals introduced potential utilization limits and bundled payment concepts that could reduce surveillance testing volume.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.